Clinical Management in Traumatic Brain Injury

Amy Yan,Andrew Torpey,Erin Morrisroe,Wesam Andraous,Ana Costa,Sergio Bergese
DOI: https://doi.org/10.3390/biomedicines12040781
IF: 4.757
2024-04-03
Biomedicines
Abstract:Traumatic brain injury is one of the leading causes of morbidity and mortality worldwide and is one of the major public healthcare burdens in the US, with millions of patients suffering from the traumatic brain injury itself (approximately 1.6 million/year) or its repercussions (2–6 million patients with disabilities). The severity of traumatic brain injury can range from mild transient neurological dysfunction or impairment to severe profound disability that leaves patients completely non-functional. Indications for treatment differ based on the injury's severity, but one of the goals of early treatment is to prevent secondary brain injury. Hemodynamic stability, monitoring and treatment of intracranial pressure, maintenance of cerebral perfusion pressure, support of adequate oxygenation and ventilation, administration of hyperosmolar agents and/or sedatives, nutritional support, and seizure prophylaxis are the mainstays of medical treatment for severe traumatic brain injury. Surgical management options include decompressive craniectomy or cerebrospinal fluid drainage via the insertion of an external ventricular drain. Several emerging treatment modalities are being investigated, such as anti-excitotoxic agents, anti-ischemic and cerebral dysregulation agents, S100B protein, erythropoietin, endogenous neuroprotectors, anti-inflammatory agents, and stem cell and neuronal restoration agents, among others.
biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
What problem does this paper attempt to address?
The paper aims to explore the clinical management and treatment methods for Traumatic Brain Injury (TBI). Specifically, the paper focuses on the following aspects: 1. **Severity and Public Health Burden of TBI**: - TBI is one of the leading causes of disability and death worldwide. In the United States, approximately 1.6 million people suffer from TBI each year, with about 50,000 deaths and 5.3 million people living with long-term TBI-related disabilities. - The direct and indirect costs of TBI amount to as much as $76.56 billion annually. 2. **Mechanisms of TBI**: - TBI can be divided into primary injuries (such as skull fractures and intracranial hemorrhage) and secondary injuries (such as brain edema and increased intracranial pressure). - Primary injuries are typically the target of preventive treatments, while secondary injuries can be intervened upon through therapeutic means. 3. **Clinical Management Methods**: - Initial assessment includes non-contrast head CT scans to detect intracranial hemorrhage, edema, etc. - Monitoring intracranial pressure (ICP) is a crucial aspect of managing TBI, especially for patients with low GCS scores. - External Ventricular Drainage (EVD) can monitor ICP and reduce intracranial pressure. - Surgical treatments include hematoma removal and decompressive craniectomy (DC), although the latter is controversial regarding long-term neurological outcomes. - Mechanical ventilation is used for patients with respiratory failure, and over-ventilation should be avoided. - Fluid therapy uses hyperosmolar agents (such as mannitol and hypertonic saline) to reduce intracranial pressure. - Antifibrinolytic drugs (such as Tranexamic Acid, TXA) used early can reduce mortality rates. In summary, the paper primarily focuses on how comprehensive clinical management and treatment methods can improve the outcomes for TBI patients, particularly by providing specific recommendations for the prevention and management of secondary brain injuries.